European Union announces new programme to improve Parkinson’s diagnosis

News

Author: Parkinson's Life editorsPublished: 17 January 2018

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

PD-Podcast-DBS

The European Union has announced the launch of the Magnetic Diagnostic Assay for Neurodegenerative Diseases (MADIA) – a project with the ultimate goal of improving diagnosis for those living with Parkinson’s and Alzheimer’s.

The project, which is in partnership with a range of international universities and institutions, will focus on the development of a novel device that will help clinicians perform a simple click and analysis to diagnose both conditions.

Dr Francisco Campos, of the Clinical Neurosciences Research Laboratory, said: “An early diagnosis is crucial to maximise the effectiveness of the treatments in order to mitigate the devastating effects of these illnesses and slow disease progression.

“MADIA is funded by the European Union’s Horizon 2020 research and innovation programme, and consists of a multitasking team with more than 50 professionals in the fields of biology, physics and engineering.”

For comprehensive information about Parkinson’s diagnosis please visit the EPDA website.

Go Back

Share this story

Comments


Related articles


Women and Parkinson's

The women blazing the trail in Parkinson’s tech and innovation

Have you heard about these Parkinson’s technology inventions?

READ MORE
Boston Scientifc experts

sponsored article

Advances

From small steps to big leaps – 200 years of Parkinson’s disease research and therapy advancements

Advice from experts working to enhance Parkinson’s therapy options

READ MORE
Heap of medical pills in white, blue and other colors. Pills in plastic package

PD in Practice

Dopamine agonists for Parkinson’s: a simple introduction

Find out more about the Parkinson’s medication

READ MORE